-
11.发明授权Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites 有权用于疾病部位的基于抗体的靶向治疗剂和识别部分的聚合物载体公开(公告)号：US08338140B2
公开(公告)日：2012-12-25
申请号：US13246389
申请日：2011-09-27
CPC分类号： A61K47/48315 , A61K31/4745 , A61K31/704 , A61K38/05 , A61K47/556 , A61K47/61 , A61K47/62 , A61K47/645 , A61K47/646 , A61K47/65 , A61K47/665 , A61K47/6951 , B82Y5/00 , C07K14/001 , C08B37/0021 , C08G83/003 , C08G83/004 , Y02A50/403
摘要： The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.
摘要翻译： 本发明涉及用于将治疗剂递送至靶细胞，组织或生物体的方法和组合物。 在优选的实施方案中，治疗剂以治疗负荷聚合物的形式递送，其可以包含许多拷贝的一种或多种治疗剂。 在更优选的实施方案中，聚合物可以与含有一种或多种半抗原如HSG的肽部分缀合。 药剂 - 聚合物 - 肽复合物可以通过例如利用双特异性或多特异性抗体或片段的预靶向技术递送至靶细胞，所述双特异性或多特异性抗体或片段具有识别半抗原的至少一个结合臂和至少一个结合的结合臂 具体涉及疾病或病原体相关抗原，例如肿瘤相关抗原。 提供了合成和使用这种治疗负载型聚合物及其共轭物的方法。
-
公开(公告)号：US08268317B2
公开(公告)日：2012-09-18
申请号：US12538922
申请日：2009-08-11
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： A61K45/06 , A61K47/60 , A61K47/6803 , A61K47/6839 , A61K47/6841 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6863 , A61K47/6865 , A61K47/6867 , A61K47/6869 , A61K47/6889 , A61K2039/505 , C07K16/1063 , C07K16/2803 , C07K16/2833 , C07K16/2863 , C07K16/30 , C07K2317/73 , Y02A50/403
摘要： The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
摘要翻译： 本发明涉及具有改进的靶向各种患有靶向部分（例如抗体或抗体片段），接头和喜树碱作为治疗部分的病变细胞的能力的治疗性缀合物，还涉及制备和使用所述缀合物的方法 。
-
13.发明申请Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases 有权用于治疗B细胞疾病的抗CD22抗体的喜树碱缀合物公开(公告)号：US20110305631A1
公开(公告)日：2011-12-15
申请号：US13213245
申请日：2011-08-19
IPC分类号： A61K51/10 , A61K38/19 , A61K38/20 , A61K38/21 , A61P35/00 , A61P35/02 , A61P37/06 , A61P13/12 , A61P7/00 , A61P3/10 , A61P29/00 , A61P25/00 , A61P1/16 , A61P17/00 , A61P17/16 , A61K39/395
CPC分类号： A61K51/1027 , A61K9/19 , A61K39/39558 , A61K47/26 , A61K47/48384 , A61K47/48561 , A61K47/4863 , A61K47/48715 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6859 , A61K47/6867 , A61K47/6883 , A61K47/6889 , A61K51/1069 , A61K51/1096 , A61K2039/505 , A61K2039/507 , A61P35/02 , C07K16/1063 , C07K16/2803 , C07K16/2833 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/3061 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2319/70
摘要： Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD22 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease.
摘要翻译： 本文公开了包含抗CD22抗体与治疗剂的组合的组合物和使用方法。 治疗剂可以在抗-CD22抗体之前，同时或之后与抗CD22抗体连接，或者可以分开施用。 在优选的实施方案中，治疗剂是与CD22，例如CD19，CD20，CD21，CD22，CD23，CD37，CD40，CD40L，CD52，CD80和HLA-DR不同的抗原结合的抗体或其片段。 然而，治疗剂可以是本领域已知的免疫调节剂，细胞因子，毒素或其它治疗剂。 更优选地，抗CD22抗体是DNL复合物的一部分，例如六价DNL复合物。 最优选地，与抗-CD22抗体或片段和治疗剂的组合治疗比单独的抗体，单独的治疗剂或者不相互结合的抗CD22抗体和治疗剂的组合更有效。 抗CD22抗体和治疗剂的施用在诸如B细胞淋巴瘤或白血病，自身免疫疾病或免疫功能障碍疾病的疾病中诱导靶细胞的凋亡和细胞死亡。
-
14.发明申请Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy 有权结合放射免疫治疗和抗体药物结合物改善癌症治疗公开(公告)号：US20110070156A1
公开(公告)日：2011-03-24
申请号：US12957655
申请日：2010-12-01
IPC分类号： A61K51/10 , A61K39/395 , A61K38/21 , A61P35/00 , C07K16/46
CPC分类号： A61K51/1057 , A61K31/4745 , A61K31/7068 , A61K39/39558 , A61K41/0038 , A61K45/06 , A61K47/643 , A61K47/6803 , A61K47/6857 , A61K47/6859 , A61K51/08 , A61K51/109 , A61K2039/505 , A61K2039/507 , B82Y5/00 , C07K16/30 , C07K16/303 , C07K16/3092 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/77 , A61K2300/00
摘要： Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.
摘要翻译： 本文描述了使用放射性核素 - 抗体缀合物（用于RAIT）和药物 - 抗体缀合物（ADC）的组合物和方法。 RAIT和ADC的组合比单独的RAIT，单独的ADC或RAIT和ADC的影响的总和更有效。 意外的协同作用导致肿瘤生长速度降低和存活率增加，裸鼠中Capan-1人胰腺癌异种移植物的无瘤生存率高。
-
15.发明申请Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites 有权治疗剂的聚合载体和用于基于抗体靶向疾病部位的识别部分公开(公告)号：US20100233779A1
公开(公告)日：2010-09-16
申请号：US12766092
申请日：2010-04-23
CPC分类号： A61K47/48315 , A61K31/4745 , A61K31/704 , A61K38/05 , A61K47/556 , A61K47/61 , A61K47/62 , A61K47/645 , A61K47/646 , A61K47/65 , A61K47/665 , A61K47/6951 , B82Y5/00 , C07K14/001 , C08B37/0021 , C08G83/003 , C08G83/004 , Y02A50/403
摘要： The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.
摘要翻译： 本发明涉及用于将治疗剂递送至靶细胞，组织或生物体的方法和组合物。 在优选的实施方案中，治疗剂以治疗负荷聚合物的形式递送，其可以包含许多拷贝的一种或多种治疗剂。 在更优选的实施方案中，聚合物可以与含有一种或多种半抗原如HSG的肽部分缀合。 药剂 - 聚合物 - 肽复合物可以通过例如利用双特异性或多特异性抗体或片段的预靶向技术递送至靶细胞，所述双特异性或多特异性抗体或片段具有识别半抗原的至少一个结合臂和至少一个结合的结合臂 具体涉及疾病或病原体相关抗原，例如肿瘤相关抗原。 提供了合成和使用这种治疗负载型聚合物及其共轭物的方法。
-
公开(公告)号：US20100104589A1
公开(公告)日：2010-04-29
申请号：US12629404
申请日：2009-12-02
IPC分类号： A61K39/395 , C07K16/00 , A61P35/04 , A61P31/00
CPC分类号： A61K47/6803 , A61K31/4745 , A61K45/06 , A61K47/6841 , A61K47/6849 , A61K47/6851 , A61K47/6853 , A61K47/6855 , A61K47/6857 , A61K47/6861 , A61K47/6889 , A61K2039/505 , A61N5/10 , C07D491/22 , C07K16/1063 , C07K16/18 , C07K16/2803 , C07K16/2833 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3076 , C07K16/3092 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/40 , C07K2317/52 , C07K2317/53 , C07K2317/94 , Y02A50/394 , Y02A50/401 , Y02A50/403 , Y02A50/412 , Y02A50/473 , Y02A50/478
摘要： The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
摘要翻译： 本发明涉及具有改善靶向各种含有靶向部分（例如抗体或抗体片段）的病变细胞，接头和治疗部分的能力的治疗性缀合物，还涉及制备和使用缀合物的方法。
-
公开(公告)号：US20100015046A1
公开(公告)日：2010-01-21
申请号：US12538922
申请日：2009-08-11
IPC分类号： A61K31/4375 , A61K51/00 , A61K31/7088 , A61K39/395 , A61K38/02 , A61P31/00 , A61P35/00
CPC分类号： A61K45/06 , A61K47/60 , A61K47/6803 , A61K47/6839 , A61K47/6841 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6863 , A61K47/6865 , A61K47/6867 , A61K47/6869 , A61K47/6889 , A61K2039/505 , C07K16/1063 , C07K16/2803 , C07K16/2833 , C07K16/2863 , C07K16/30 , C07K2317/73 , Y02A50/403
摘要： The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
摘要翻译： 本发明涉及具有改进的靶向各种患有靶向部分（例如抗体或抗体片段），接头和喜树碱作为治疗部分的病变细胞的能力的治疗性缀合物，还涉及制备和使用所述缀合物的方法 。
-
公开(公告)号：US08574575B2
公开(公告)日：2013-11-05
申请号：US13293608
申请日：2011-11-10
IPC分类号： A61K39/395
CPC分类号： A61K45/06 , A61K39/39558 , A61K51/1045 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K2317/21 , C07K2317/24
摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
-
19.发明授权Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases 有权用于治疗B细胞疾病的抗CD22抗体的喜树碱缀合物公开(公告)号：US08420086B2
公开(公告)日：2013-04-16
申请号：US13213245
申请日：2011-08-19
CPC分类号： A61K51/1027 , A61K9/19 , A61K39/39558 , A61K47/26 , A61K47/48384 , A61K47/48561 , A61K47/4863 , A61K47/48715 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6859 , A61K47/6867 , A61K47/6883 , A61K47/6889 , A61K51/1069 , A61K51/1096 , A61K2039/505 , A61K2039/507 , A61P35/02 , C07K16/1063 , C07K16/2803 , C07K16/2833 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/3061 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2319/70
摘要： Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD22 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease.
摘要翻译： 本文公开了包含抗CD22抗体与治疗剂的组合的组合物和使用方法。 治疗剂可以在抗-CD22抗体之前，同时或之后与抗CD22抗体连接，或者可以分开施用。 在优选的实施方案中，治疗剂是与CD22，例如CD19，CD20，CD21，CD22，CD23，CD37，CD40，CD40L，CD52，CD80和HLA-DR不同的抗原结合的抗体或其片段。 然而，治疗剂可以是本领域已知的免疫调节剂，细胞因子，毒素或其它治疗剂。 更优选地，抗CD22抗体是DNL复合物的一部分，例如六价DNL复合物。 最优选地，与抗-CD22抗体或片段和治疗剂的组合治疗比单独的抗体，单独的治疗剂或者不相互结合的抗CD22抗体和治疗剂的组合更有效。 抗CD22抗体和治疗剂的施用在诸如B细胞淋巴瘤或白血病，自身免疫疾病或免疫功能障碍疾病的疾病中诱导靶细胞的凋亡和细胞死亡。
-
公开(公告)号：US20120328564A1
公开(公告)日：2012-12-27
申请号：US13586541
申请日：2012-08-15
IPC分类号： A61K39/395 , A61P31/14 , A61P31/20 , A61P33/02 , A61P31/10 , A61P33/00 , A61P31/18 , A61P31/00 , A61P31/04
CPC分类号： A61K45/06 , A61K47/60 , A61K47/6803 , A61K47/6839 , A61K47/6841 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6863 , A61K47/6865 , A61K47/6867 , A61K47/6869 , A61K47/6889 , A61K2039/505 , C07K16/1063 , C07K16/2803 , C07K16/2833 , C07K16/2863 , C07K16/30 , C07K2317/73 , Y02A50/403
摘要： The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.
摘要翻译： 本发明涉及具有改进的靶向各种患有靶向部分（例如抗体或抗体片段），接头和喜树碱作为治疗部分的病变细胞的能力的治疗性缀合物，还涉及制备和使用所述缀合物的方法 。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.029 秒)
